# Multiple Myeloma Frontier Completion Audit Handoff v0

Stewarded by [frg.earth](https://frg.earth/).

- disease program: `multiple-myeloma`
- artifact id: `multiple-myeloma-frontier-completion-audit-handoff-v0`
- frontier status: `frontier-v0-completion-audited`
- claim level: open-question
- clinical boundary: research-use-only, not medical advice
- completion boundary: public frontier loop completion, not scientific or
  clinical completion
- last reviewed: `2026-04-16`

## Purpose

This handoff audits the public multiple myeloma frontier loop after all eight
frontier lanes have a first useful public artifact, metadata, catalog coverage,
navigation links, and validation coverage.

It exists to prevent the next autonomous pass from inventing another sibling
lane after the frontier roadmap's named range has ended.

This handoff does not claim that multiple myeloma has been cured. It does not
complete expert review, clinical review, private-lab review, publication
review, or any patient-specific workflow.

## Phase Handoff Guard

| Check | Finding | Handoff Decision |
| --- | --- | --- |
| Named endpoint | The frontier roadmap completion matrix names an aggregate frontier completion audit or handoff after the public translation lane. | Use this aggregate handoff as the finite endpoint for frontier v0. |
| Lane range | Lanes 1 through 8 now each have a first public artifact or explicit bounded successor. | Do not add a lane 9 by momentum. |
| Ready task queue | `make list-public-tasks ARGS="--status ready"` reports zero ready tasks. | Do not select a new public task without a new project-owned phase gate. |
| Validation gate | `make validate` must pass after this handoff is wired. | Treat validation failure as a blocker; otherwise close the frontier v0 loop. |
| Generalization opportunity | Remaining work spans expert responses, source extraction, private-lab case work, human review, and future phase selection. | Record a single aggregate handoff instead of extending a local ladder. |
| Next unresolved range | No open frontier lane range remains in the roadmap. | Future autonomous work needs a new named phase, not another frontier-lane sibling. |

## Completion Audit

| Frontier Definition-Of-Complete Criterion | Status | Public Basis | Residual Boundary |
| --- | --- | --- | --- |
| Every frontier lane has a first public artifact or explicit public-safe blocked status. | Complete for frontier v0. | See the lane matrix below. | Future work needs a new named gate or task model. |
| Every new artifact has metadata and catalog coverage. | Complete after this handoff is cataloged. | [Public Artifact Catalog v0](../../artifacts/public-artifact-catalog-v0.md) and metadata files track the frontier artifacts. | Re-run validation before release or future edits. |
| Disease-program README and protocol index make the frontier navigable. | Complete after this handoff is linked. | The disease README links the frontier roadmap, lane artifacts, and this handoff; the protocol index links the frontier delegation packet and this handoff. | Navigation does not imply clinical readiness. |
| Expert validation issues have public-safe statuses and next actions. | Complete for public v0 status mapping. | [Expert Response Validation Ledger v0](reviews/expert-response-validation-ledger-v0.md) maps issues #22 through #34 to public-safe dispositions and next actions. | Expert-review-needed remains until safe public responses are reviewed. |
| MRD and endpoint language has guardrails against cure overclaiming. | Complete for frontier v0. | [MRD Endpoint Language Guardrail Addendum v0](measurements/mrd-endpoint-language-guardrail-addendum-v0.md). | Source extraction and expert review remain useful next work. |
| Immune therapy and trial references are date-scoped and non-advisory. | Complete for boundary layer. | [Immune Therapy Sequencing And Access Boundary v0](therapy-landscapes/immune-therapy-sequencing-access-boundary-v0.md). | No product availability, eligibility, sequencing, or access advice. |
| Post-BCMA resistance gaps have public task coverage. | Complete for first frontier map. | [Post-BCMA Resistance Frontier Addendum v0](mechanisms/post-bcma-resistance-frontier-addendum-v0.md), BCMA evidence gaps, and mechanism task queues. | No mechanism ranking, patient relevance, or product comparison. |
| Precursor and high-risk context language is bounded and non-directive. | Complete for first boundary layer. | [Precursor, Risk, And Interception Boundary Note v0](precursors/precursor-risk-interception-boundary-note-v0.md) and [Context Modifier Map v0](contexts/high-risk-organ-frailty-context-modifier-map-v0.md). | No screening, personal risk, prognosis, eligibility, monitoring, or treatment guidance. |
| Case-to-cure dry run maps every stage to owner artifacts, validators, and blockers. | Complete for public v0 dry-run map. | [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md), blueprint, synthetic example, and blocker register. | Real case work remains private-lab or human-gated. |
| Public translation artifacts make contribution safer for non-specialists. | Complete for first public surface. | [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md). | Plain-language review may improve readability, but it is not a clinical review. |
| Remaining work is labeled as expert-review-needed, private-lab-needed, clinical-team-needed, or human-publication-gate-needed. | Complete for frontier v0. | This handoff and lane artifacts keep residual work behind explicit blockers. | Blockers remain blockers until a qualified human or new phase resolves them. |

## Lane Matrix

| Lane | First Frontier Artifact | What It Helps Inspect | What It Cannot Be Used For | Safe Successor |
| --- | --- | --- | --- | --- |
| Expert response intake | [Expert Response Validation Ledger v0](reviews/expert-response-validation-ledger-v0.md) | Public issue status, safe dispositions, artifact paths, and next actions. | Copying private correspondence, declaring consensus, or completing expert review. | Public-source-backed disposition updates only after safe review. |
| MRD and endpoints | [MRD Endpoint Language Guardrail Addendum v0](measurements/mrd-endpoint-language-guardrail-addendum-v0.md) | Method, sample, threshold, timepoint, durability, endpoint status, and limitations. | Cure claims, prognosis, treatment choice, monitoring, or clinical interpretation. | MRD endpoint source extraction task using public sources. |
| Immune therapy sequencing | [Immune Therapy Sequencing And Access Boundary v0](therapy-landscapes/immune-therapy-sequencing-access-boundary-v0.md) | Date-scoped status fields for immune therapy classes, targets, trials, and products. | Availability, eligibility, sequencing, access, urgency, or ranking advice. | Validated non-advisory therapy landscape records. |
| Post-BCMA resistance | [Post-BCMA Resistance Frontier Addendum v0](mechanisms/post-bcma-resistance-frontier-addendum-v0.md) | Mechanism claim levels, contradiction fields, and source-backed gaps. | Patient-specific mechanism inference, therapy comparison, or option selection. | Contradiction-register shape before dashboards or scoring. |
| Precursor and interception | [Precursor, Risk, And Interception Boundary Note v0](precursors/precursor-risk-interception-boundary-note-v0.md) | MGUS, smoldering myeloma, risk, interception, and prevention-adjacent wording boundaries. | Screening advice, personal risk calculation, trial fit, monitoring, or prevention claims. | Source extraction for definitions and cohort-level risk context. |
| High-risk and context | [Context Modifier Map v0](contexts/high-risk-organ-frailty-context-modifier-map-v0.md) | Optional, source-scoped disease, organ, frailty, immune, and exposure context labels. | Prognosis, eligibility, treatment intensity, transplant fit, or option ranking. | Case-feature addendum only after a bounded schema lane selects optional fields. |
| Case-to-cure plumbing | [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md) | Stage owner artifacts, validators or gates, blocked conditions, and allowed public successors. | Public case processing, packet assembly, patient matching, trial matching, or recommendations. | Structured graph or fixture expansion only inside a new bounded phase. |
| Public translation | [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md) | Safe entry points, glossary anchors, task chooser, review task map, and refusal rules. | Patient guide, clinical explainer, trial guide, screening guide, or cure claim. | Human/plain-language review or issue-template edits after specific safe gaps are found. |

## Handoff Decision

The multiple myeloma frontier v0 public autonomous loop is complete for its
stated public definition of complete after this artifact is cataloged and
validation passes.

No new ready public task is selected by this handoff.

Future work should begin only as one of these:

- human protected-branch review of the current public artifact set
- public-source-backed disposition updates for issues #22 through #34
- a new named source-extraction phase with explicit source IDs, claim limits,
  and validation requirements
- a new named schema or tooling gate that proves no generated claims, no
  patient matching, no trial matching, no ranking, and no clinical guidance
- private-lab work outside this repo when real case data, consent, clinical
  review, or publication decisions are required
- a blocker report when the requested next step requires credentials, paid
  services, external decisions, private data, clinical judgment, or publication
  authorization

## Public Safety Check

- No patient-identifying data.
- No real case data.
- No private records.
- No credentials, paid APIs, account changes, or restricted datasets.
- No diagnosis, prognosis, treatment, trial, eligibility, expanded-access,
  screening, monitoring, safety-management, or personal-risk advice.
- No target, therapy, trial, source, mechanism, artifact, task, evidence, or
  option ranking.
- No generated biomedical claims.
- No copied private correspondence.
- No expert-review substitution.
- No publication authorization.
- No cure or vaccine claim.

## Limitations

- This handoff is a public completion audit, not a scientific review.
- This handoff does not prove source coverage is comprehensive.
- This handoff does not grade evidence quality.
- This handoff does not make any artifact expert-reviewed.
- This handoff does not make any artifact clinical-review-complete.
- This handoff does not make any artifact publication-ready.
- This handoff does not inspect private lab records or real case data.
- This handoff does not complete any private-lab task or human-gated decision.
- This handoff does not authorize review-packet assembly, generated packet
  output, generated claims, ranking, recommendation behavior, patient matching,
  trial matching, or publication workflow.
- This handoff does not authorize public case processing or public case upload.
- This handoff does not provide medical advice, diagnostic guidance, treatment
  guidance, trial guidance, eligibility guidance, expanded-access guidance,
  screening guidance, monitoring guidance, or personal-risk guidance.
- This handoff does not claim that multiple myeloma has been cured or that any
  vaccine has been found.
